Phase 4
Completed N=5
Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
Source: ClinicalTrials.gov NCT05439460 ↗Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Aug 2022
Primary outcomePrimary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9
◆ Published Evidence
Established
60citations · ~6 / year
Hemodynamic Effects of Phenylephrine, Vasopressin, and Epinephrine in Children With Pulmonary Hypertension: A Pilot Study.
Summary
Pulmonary arterial hypertension (PAH) is a disease where the blood pressure in the pulmonary arteries (PAP) is high. PAH increases the risk of adverse events, including death, during and or after procedures. The severity of baseline PAH correlates with the incidence of major complications, such that those with PAP higher than their systemic blood pressure (SBP) had a 8 fold increased risk of complications. These children present for procedures where an acute exacerbation of their chronic illness-termed Pulmonary Hypertensive (PH)crisis, can occur, often resulting in death if not detected and managed expeditiously. Unfortunately there is little data and no consensus in the pediatric literature on how PH crisis should be managed.
--------------------------------------------------------------------------------
Linked Publications
-
Hemodynamic Effects of Phenylephrine, Vasopressin, and Epinephrine in Children With Pulmonary Hypertension: A Pilot Study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) |
0.8; 0.75; 0.61; 0.73; 0.49; 0.6 | 0.9 |
Eligibility Criteria
Inclusion Criteria
- Patients presenting for cardiac catheterization procedure with a diagnosis of PAH either by previous cardiac catheterization or echocardiography
Exclusion Criteria
- Children presenting for cardiac catheterization who do not have PAH;
- Children with PAH but with intracardiac shunts
Data sourced from ClinicalTrials.gov (NCT05439460) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.